Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.59+0.00 (+0.29%)

Close on Nov 11, 2026Market cap $164.37MP/E –Yield –

Humacyte cash

Cash and short-term investments held at the end of each period.

Humacyte's cash was $64.52M at Sep 30, 2026. For fiscal 2025 it was $50.50M, down 47.0% from the year before. The highest annual figure on record is $225.50M in fiscal 2021.

Annual cash

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$50.50M	-47.0%
FY2024	Dec 31, 2024	$95.29M	+18.5%
FY2023	Dec 31, 2023	$80.40M	-47.1%
FY2022	Dec 31, 2022	$151.90M	-32.6%
FY2021	Dec 31, 2021	$225.50M	+464.8%
FY2020	Dec 31, 2020	$39.93M	-57.4%
FY2019	Dec 31, 2019	$93.71M	–

Quarterly cash

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$64.52M	+225.2%
Q2 FY2026	Jun 30, 2026	$79.90M	-9.6%
Q1 FY2026	Mar 31, 2026	$48.54M	-57.1%
Q4 FY2025	Dec 31, 2025	$50.50M	-47.0%
Q3 FY2025	Sep 30, 2025	$19.84M	-72.0%
Q2 FY2025	Jun 30, 2025	$88.39M	-5.9%
Q1 FY2025	Mar 31, 2025	$113.20M	-2.3%
Q4 FY2024	Dec 31, 2024	$95.29M	+18.5%
Q3 FY2024	Sep 30, 2024	$70.92M	-29.3%
Q2 FY2024	Jun 30, 2024	$93.92M	-18.1%
Q1 FY2024	Mar 31, 2024	$115.86M	-12.0%
Q4 FY2023	Dec 31, 2023	$80.40M	-47.1%
Q3 FY2023	Sep 30, 2023	$100.34M	-41.6%
Q2 FY2023	Jun 30, 2023	$114.60M	-39.4%
Q1 FY2023	Mar 31, 2023	$131.70M	-36.1%
Q4 FY2022	Dec 31, 2022	$151.90M	-32.6%
Q3 FY2022	Sep 30, 2022	$171.70M	-28.6%
Q2 FY2022	Jun 30, 2022	$189.00M	+552.4%
Q1 FY2022	Mar 31, 2022	$206.20M	+362.0%
Q4 FY2021	Dec 31, 2021	$225.50M	+464.8%
Q3 FY2021	Sep 30, 2021	$240.45M	+333.5%
Q2 FY2021	Jun 30, 2021	$28.97M	-69.1%
Q1 FY2021	Mar 31, 2021	$44.63M	–
Q4 FY2020	Dec 31, 2020	$39.93M	–
Q3 FY2020	Sep 30, 2020	$55.46M	–
Q4 FY2019	Dec 31, 2019	$93.71M	–